Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Viracta Therapeutics Inc

RYI
Current price
0.17 EUR 0 EUR (0.00%)
Last closed 0.22 USD
ISIN US92765F1084
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 9 893 717 USD
Yield for 12 month -79.96 %
1Y
3Y
5Y
10Y
15Y
RYI
21.11.2021 - 28.11.2021

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Address: 2533 South Coast Highway 101, Cardiff, CA, United States, 92007

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-492 000 USD

Last Year

-210 000 USD

Current Quarter

-96 000 USD

Last Quarter

-110 000 USD

Key Figures RYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -49 044 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -57.2 %
PEG Ratio
Return On Equity TTM -208.67 %
Wall Street Target Price 3.5 USD
Revenue TTM
Book Value -0.071 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.16 USD
Diluted Eps TTM -1.16 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics RYI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History RYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 285:1000
Payout Ratio
Last Split Date 25.02.2021
Dividend Date 03.09.2020

Stock Valuation RYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.4797
Price Book MRQ 2.4318

Financials RYI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators RYI

For 52 weeks

0.2 USD 1.31 USD
50 Day MA 0.39 USD
Shares Short Prior Month 2 535 132
200 Day MA 0.63 USD
Short Ratio 0.92
Shares Short 1 260 272
Short Percent 4.07 %